ABSTRACT

Mononoclonal antibodies have been found to be more effective in treating various types of diseases because they are more targeted than some other forms of medications. The use of mAbs in cancer, autoimmune disorders, chronic illnesses, and a number of other conditions has previously been authorised. Numerous biopharmaceutical firms attempt to compete by creating monoclonal antibodies and moving them forward into clinical trials due to their extensive potential as immunotherapeutics. Some monoclonal antibodies are also used in immunotherapy to aid the immune system's fight against cancer. Some monoclonal antibodies, for example, mark cancer cells so that the immune system can detect and kill them more effectively. In a recent clinical experiment, it was discovered that Dostarlimab completely cured all CRC patients who received it, with no patients experiencing any grade 3 or above side effects. A humanised monoclonal antibody called dostarlimab (Jemperli) or dostarlimab-gxly functions as an antagonist for programmed death-1 (PD-1) receptors. Moreover, clinical trial data showed dostarlimab is more effective than other PD-1 inhibitors and no significant adverse effects in any of the research participants, The purpose of this study is to summarise current evidence about monoclonal antibodies for cancer treatment and New drug Dostarlimab and to assess the possibility for Novel and Combination therapy. Keyword: Monoclonal antibody therapy, PD1 anatgonist , Immunotherapy , Dostarlimab, Endometrial cancer
Publication date: 01/09/2023

https://ijbpas.com/pdf/2023/September/MS_IJBPAS_2023_7420.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.9.7420